Biotech company Acuitas Therapeutics and Germany-based CureVac have settled Acuitas' lawsuit demanding credit for inventions ...
Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit over ...
CureVac and Acuitas Therapeutics have settled their COVID-19 vaccine dispute. According to a filing, submitted April 25, 2024 ...
GSK said in the lawsuit , opens new tab that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the ...
Shares of biopharmaceutical company CureVac touched a new low on Wednesday following news the company, together with GSK, ended a pandemic agreement with Germany and will implement an ...
Market forces rained on the parade of CureVac N.V. (NASDAQ:CVAC) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates ...
CureVac is asserting its intellectual property rights in litigation against Pfizer/BioNTech in Germany, the U.S. and the UK. In the U.S., a magistrate judge recently granted a motion by Acuitas ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Acuitas said CureVac omitted its scientists ... within an ongoing lawsuit in Virginia federal court. In July 2023, Pfizer and BioNTech filed a complaint with the U.S. District Court in ...
enables progressing to Part B with expected start mid-2024 CureVac to host conference call and webcast today at 9 a.m. ET / 3 p.m. CET TÜBINGEN, GERMANY and HOUSTON, TX / ACCESSWIRE / April 24 ...
Benzinga - by Vandana Singh, Benzinga Editor. Canadian Biotech company Acuitas Therapeutics and Germany-based CureVac NV (NASDAQ:CVAC) have settled Acuitas’ lawsuit over credit for inventions tied to ...